Nuveen
ALT icon

Nuveen’s Altimmune ALT Stock Holding History

Nuveen’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-467,400
Closed -$6K – 3174
2022
Q3 		$6K Buy
+467,400
New +$6.9M ﹤0.01% 3195

Other funds holding ALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen's ALT Position: Q2 2026 in Review

Nuveen increased its Altimmune (ALT) stake by 3% in Q2 2026, buying an estimated $211K and bringing the position to 2,405,354 shares worth $7.31M. The position accounts for ﹤0.01% of the portfolio, ranked #1892.

Nuveen first reported a position in ALT in Q2 2021 and has held it in 21 quarters since. The position peaked at $53.7M in Q4 2022. 211 funds tracked by Wall St. Rank hold ALT as of Q2 2026.

  • Nuveen held 2,405,354 shares of Altimmune worth $7.31M as of Q2 2026.
  • Nuveen bought 70,753 Altimmune shares in Q2 2026, an estimated $211K.
  • Altimmune made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #1892 holding.
  • Nuveen first reported a position in Altimmune in Q2 2021 and has held it in 21 quarters since.
  • Nuveen's Altimmune position peaked at $53.7M in Q4 2022.
  • 211 funds tracked by Wall St. Rank held Altimmune as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.